cdk 4/6 inhibitor, palbociclib, for the treatment of metastatic breast cancer
Published 9 years ago • 2.3K plays • Length 5:43Download video MP4
Download video MP3
Similar videos
-
7:59
what are cdk 4/6 inhibitors for breast cancer?
-
17:54
expert perspectives: cdk 4/6 inhibitors for er breast cancer: current data and clinical use
-
3:33
cdk 4/6 inhibitors in metastatic breast cancer
-
2:11
the use of frontline cdk4/6 inhibitors endocrine therapy in metastatic breast cancer
-
4:54
monarch 3 study: cdk4/6 inhibitors in the treatment of metastatic breast cancer
-
4:35
hr breast cancer: differences between cdk4/6 inhibitors
-
7:40
cdk4/6 inhibitors in the first-line treatment setting
-
1:20
dr. finn on new cdk 4/6 inhibitors for breast cancer
-
13:05
expert perspectives: cdk 4/6 inhibitor therapy for er metastatic breast cancer
-
6:29
study of palbociclib after cdk & endocrine therapy in er /her2- metastatic breast cancer
-
5:01
cdk4/6 inhibitors: sequencing endocrine therapy for metastatic breast cancer
-
2:24
differentiating factors of abemaciclib among the cdk 4/6 inhibitors for breast cancer
-
1:36
dr. mahtani on the use of cdk 4/6 inhibitors in metastatic er breast cancer
-
3:03
integrating palbociclib into the treatment of breast cancer
-
3:27
metastatic breast cancer: cdk4/6 inhibitors
-
1:08
overcoming resistance to cdk4/6 inhibitors in er breast cancer via ctdna
-
39:21
bcfnz webinar: palbociclib (ibrance) for advanced or metastatic hr breast cancer - nz update
-
29:09
interactive case: choosing and using cdk4/6 inhibitors in breast cancer - first-line therapy
-
2:06
unmet needs and cdk4/6 inhibitors in hr /her2- early breast cancer